Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01.12.08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01.12.08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01.01.17 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 04.12. |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 25.10.22 |
Delly Behen
ADM | Chief Administrative Officer | - | 01.01.14 |
Eric van Zanten
IRC | Investor Relations Contact | - | 07.12.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01.12.08 |
Director/Board Member | 66 | 01.03.14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01.02.12 |
Shu-Chih Chen
FOU | Founder | 62 | 01.12.08 |
Stephen Galli
BRD | Director/Board Member | 77 | 01.07.11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 08.11. |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 127 077 462 | 125 230 652 ( 98,55 %) | 0 | 98,55 % |
Aktie B | 0 | 582 | 0 | 0 |
Unternehmenskontakt
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+29,77 % | 49,46 Mrd. | |
+1,00 % | 42,58 Mrd. | |
+49,62 % | 42,49 Mrd. | |
-5,26 % | 29,09 Mrd. | |
+13,68 % | 26,61 Mrd. | |
-22,99 % | 18,64 Mrd. | |
+8,22 % | 13,16 Mrd. | |
+32,41 % | 12,55 Mrd. | |
+24,01 % | 12,1 Mrd. |